Built by Scientists. Backed by Clinical Research.
NextEvo was founded by former Johnson & Johnson executives who saw a CBD industry built on marketing, not science. The real problem was delivery: oil-based CBD is poorly absorbed, and most of it never reaches the bloodstream. Our founders solved it. The result is SmartSorb™: a patented, water-soluble CBD technology validated in peer-reviewed clinical trials.
*Based on Abbotts et al., Nutrients 2022 (AUC comparison vs. oil-based formulation). See the science.
Our Mission
To apply pharmaceutical-grade science to CBD, and deliver products that actually perform. Every NextEvo formula is clinically tested and independently verified — held to the same standards we upheld in pharmaceuticals.
By the Numbers
30+
Patents in drug delivery and pharmaceutical formulation
50+ Years
Combined pharmaceutical R&D, clinical development and commercialization
Clinical Trials
Peer-reviewed research validating SmartSorb™ absorption and onset superiority
Gerry McNally, Ph.D.
Gerry brings more than 25 years of pharmaceutical R&D leadership to NextEvo, including a career at McNeil Consumer Healthcare and Johnson & Johnson where he led development of some of the most recognized OTC products on the market — including Tylenol® Rapid Release Gels, Imodium® Multi-Symptom Relief, and Pepcid® Complete. He holds 30+ patents in drug delivery and pharmaceutical formulation, and was instrumental in several major Rx-to-OTC switches including Pepcid® AC and Zyrtec®. His expertise in bioavailability and novel delivery systems is the foundation of SmartSorb™ technology. Gerry earned his Ph.D. and BSc Honours in Chemistry from University College Dublin.
David Chernoff, MD
Dr. Chernoff is a molecular diagnostics and biopharmaceutical veteran with more than 25 years of global clinical development experience. He has served as Chief Medical Officer for multiple companies including Adamas Pharmaceuticals, Aquinox, Crescendo Bioscience, Schiff Nutrition, and SetPoint Medical — leading early-stage R&D programs through clinical validation and commercialization. At NextEvo, Dr. Chernoff oversees the clinical research behind SmartSorb™ technology. His work includes clinical trials demonstrating up to 4.5x superior absorption* versus oil-based CBD products. Dr. Chernoff is a graduate of Yale University and NYU Grossman School of Medicine, with a specialty interest in anti-inflammatory science.
*Sources: Hobbs et al., Phytotherapy Research 2020; Williams et al., Pharmaceuticals 2021; Abbotts et al., Nutrients 2022. See the science.
The Science Speaks for Itself
NextEvo is the only CBD brand with this depth of pharmaceutical expertise behind it. See how SmartSorb™ technology works — or explore our product range and experience the difference for yourself.